NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Forecast, Price & News $4.08 +0.03 (+0.74%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$3.93▼$4.1050-Day Range$3.10▼$5.3552-Week Range$2.81▼$13.40Volume14,870 shsAverage Volume22,614 shsMarket Capitalization$15.19 millionP/E RatioN/ADividend YieldN/APrice Target$55.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Akari Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,248.0% Upside$55.00 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector642nd out of 969 stocksPharmaceutical Preparations Industry305th out of 455 stocks 3.5 Analyst's Opinion Consensus RatingAkari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.00, Akari Therapeutics has a forecasted upside of 1,248.0% from its current price of $4.08.Amount of Analyst CoverageAkari Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.46% of the float of Akari Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently increased by 116.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKTX. Previous Next 2.7 News and Social Media Coverage News SentimentAkari Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Akari Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Akari Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akari Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkari Therapeutics has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akari Therapeutics (NASDAQ:AKTX) StockAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)September 28, 2023 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 116.5% in SeptemberSeptember 29, 2023 | Stansberry Research (Ad)1907, 1929, 1998, 2007--and now 2023?Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.September 27, 2023 | finance.yahoo.comAkari Therapeutics to Present at Emerging Growth ConferenceSeptember 21, 2023 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax CreditSeptember 21, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.comSeptember 19, 2023 | finance.yahoo.comAkari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet NeedsSeptember 5, 2023 | finance.yahoo.comAkari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 29, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 31, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10August 21, 2023 | finance.yahoo.comBritish pharma opens U.S. headquarters in BostonAugust 18, 2023 | finance.yahoo.comAkari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical TrialsAugust 17, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces ADS Ratio ChangeAugust 15, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics, Plc Announces ADS Ratio ChangeAugust 15, 2023 | msn.comAkari Therapeutics announces ADS ratio changeAugust 15, 2023 | finance.yahoo.comAkari Therapeutics, Plc Announces ADS Ratio ChangeAugust 2, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory AffairsAugust 2, 2023 | finance.yahoo.comAkari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory AffairsJuly 27, 2023 | finance.yahoo.comAkari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell TransplantationJuly 19, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial OfficerJuly 19, 2023 | finance.yahoo.comAkari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial OfficerJuly 15, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMAJuly 13, 2023 | finance.yahoo.comAkari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMAJuly 11, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic AtrophyJuly 11, 2023 | finance.yahoo.comAkari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic AtrophyJuly 6, 2023 | marketwatch.comAkari Therapeutics Shares Rise 22% After Nomacopan's Positive Orphan Drug Opinion in EuropeJuly 6, 2023 | finance.yahoo.comAkari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell TransplantationSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKTX Company Calendar Last Earnings3/31/2020Today9/29/2023Next Earnings (Estimated)9/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$55.00 High Stock Price Forecast$80.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+1,248.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book8.50Miscellaneous Outstanding Shares3,723,000Free Float1,422,000Market Cap$15.19 million OptionableNot Optionable Beta1.40 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 52)Pres, CEO & Director Comp: $1.38MMs. Wendy F. DiCicco CPA (Age 56)CPA, Interim Chief Financial Officer Ms. Melissa Bradford-Klug (Age 53)Chief Operating Officer Dr. Miles Nunn (Age 54)Chief Scientific Officer Dr. John F. Neylan III (Age 70)M.D., Exec. VP & Chief Medical Officer Ms. Beth-Anne LangSr. VP of Regulatory AffairsAnnie MackFinancial ControllerMore ExecutivesKey CompetitorsOnconova TherapeuticsNASDAQ:ONTXGalectoNASDAQ:GLTOAprea TherapeuticsNASDAQ:APRENightHawk BiosciencesNYSE:NHWKCalciMedicaNASDAQ:CALCView All CompetitorsInstitutional OwnershipCerity Partners LLCBought 322,862 shares on 8/14/2023Ownership: 0.434%View All Institutional Transactions AKTX Stock - Frequently Asked Questions Should I buy or sell Akari Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares. View AKTX analyst ratings or view top-rated stocks. What is Akari Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 1 year target prices for Akari Therapeutics' shares. Their AKTX share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 1,248.0% from the stock's current price. View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts. How have AKTX shares performed in 2023? Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX stock has decreased by 56.6% and is now trading at $4.08. View the best growth stocks for 2023 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 17,100 shares, an increase of 116.5% from the August 31st total of 7,900 shares. Based on an average daily volume of 30,800 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.5% of the shares of the company are sold short. View Akari Therapeutics' Short Interest. When is Akari Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, September 29th 2023. View our AKTX earnings forecast. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). What is Akari Therapeutics' stock symbol? Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX." How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akari Therapeutics' stock price today? One share of AKTX stock can currently be purchased for approximately $4.08. How much money does Akari Therapeutics make? Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $15.19 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($7.00) on an earnings per share basis. How can I contact Akari Therapeutics? Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352. This page (NASDAQ:AKTX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.